Key result
Quinapril plus furosemide improves symptoms and breeding ability in stallions with mitral valve regurgitation.
Why the study?
Mitral valve disease is the most important valvular condition affecting athletic performance in horses, but detailed clinical descriptions and therapeutic outcomes in Thoroughbred stallions are limited.
Does therapy with Quinapril and Furosemide improve clinical symptoms in Thoroughbred stallions with mitral valve regurgitation?
Case Report (n=2)
Does therapy with Quinapril and Furosemide improve clinical symptoms in Thoroughbred stallions with mitral valve regurgitation?
Quinapril and furosemide therapy provided symptomatic clinical improvement in two Thoroughbred stallions with mitral valve regurgitation.
May support symptomatic use in equine mitral regurgitation; leaves open need for controlled trials before broader adoption.
Mitral valve (MV) disease is the most important valvular condition affecting athletic performance in horses. Twenty and 22 years old Thoroughbred Stallions used for breeding had suffered from increased respiratory and heart rate, poor performance and incomplete ejaculate release during covering, since three months ago. Cardiac examination projected irregular cardiac rhythm after a halt and an early-mid-systolic murmur. Mitral regurgitation (MR) and valvular changes were visible on echocardiography. Also volume overload of the Left Atrium (LA) and Left Ventricle (LV) were observed. Color Flow Doppler echocardiography confirmed moderate mitral valve regurgitation. A band-like fibrous and nodular degeneration of the left coronary leaflet was present. There was minimal secondary left ventricular remodeling of the apex of the left ventricle due to chronic volume overload. The therapeutic attempts included Quinapril and Furosemide. In these cases, normally no structural effect could be achieved, but clinical improvement and successful covering sessions were obtained, and when the therapy was terminated, clinical problems reappeared. In conclusion, in horses with MR, early diagnosis and appropriate therapy with Quinapril promises a reasonable performance.
No takes yet. Share an insight, caveat, or question.
Pınar et al. (2016) conducted a case report in Mitral valve regurgitation (n=2). Quinapril and Furosemide vs. Baseline (before treatment) was evaluated on Clinical improvement and breeding ability. Treatment with quinapril and furosemide in two stallions with mitral valve regurgitation improved clinical symptoms, stroke volume, cardiac output, and breeding ability, though symptoms relapsed upon cessation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: